logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10214585 B1

PDFFull Text
Date of Patent:
Feb. 26, 2019

Filed:

Sep. 10, 2015

Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns

Applicant:

Yeda Research and Development Co. Ltd, Rehovot, IL;

Inventors:

Michal Eisenbach-Schwartz, Rehovot, IL;

Kuti Baruch, Rehovot, IL;

Neta Rosenzweig, Rehovot, IL;

Assignee:

Yeda Research and Development Co., Ltd., Rehovot, IL;

Attorneys:

UltimatEdge IP Law Group, P.C.

Dean G. Stathakis

Primary Examiner:

Ilia I Ouspenski

Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 38/00 (2006.01); A61K 31/4155 (2006.01); A61K 38/16 (2006.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 38/14 (2006.01); A61K 45/06 (2006.01); A61K 31/404 (2006.01); A61K 31/7068 (2006.01); A61K 33/36 (2006.01); A61K 38/02 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 31/404 (2013.01); A61K 31/4155 (2013.01); A61K 31/7068 (2013.01); A61K 33/36 (2013.01); A61K 38/00 (2013.01); A61K 38/005 (2013.01); A61K 38/02 (2013.01); A61K 38/14 (2013.01); A61K 38/168 (2013.01); A61K 38/18 (2013.01); A61K 38/208 (2013.01); A61K 39/395 (2013.01); A61K 39/39541 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); A61K 2039/572 (2013.01); A61K 2121/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01);
Abstract

A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Find Patent Forward Citations

Eisenbach-Schwartz, Michal. (2019). Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns (U.S. Patent No. 10214585). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10214585

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…